Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
2003 2
2004 1
2006 1
2016 1
2017 3
2018 4
2019 3
2020 7
2021 10
2022 12
2023 3
2024 8
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A, González-Cantero A, Khattri S, Muzy G, Malatestinic WN, Lampropoulou A, Feely M, See SK, Mert C, Blauvelt A. Armstrong A, et al. Among authors: malatestinic wn. Dermatol Ther (Heidelb). 2024 Apr;14(4):933-952. doi: 10.1007/s13555-024-01136-w. Epub 2024 Mar 23. Dermatol Ther (Heidelb). 2024. PMID: 38521874 Free PMC article.
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
Armstrong AW, Jaleel T, Merola JF, Gottlieb AB, Khattri S, Helt CC, Malatestinic WN, Ross SE, Ngantcha ME, de Vlam K. Armstrong AW, et al. Among authors: malatestinic wn. Dermatol Ther (Heidelb). 2024 Jun;14(6):1615-1631. doi: 10.1007/s13555-024-01188-y. Epub 2024 May 30. Dermatol Ther (Heidelb). 2024. PMID: 38814433 Free PMC article.
Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review.
Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB. Murage MJ, et al. Among authors: malatestinic wn. Patient Prefer Adherence. 2018 Aug 21;12:1483-1503. doi: 10.2147/PPA.S167508. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 30174415 Free PMC article. Review.
Disease response and patient-reported outcomes among initiators of ixekizumab.
Shahriari M, Harrison RW, Burge R, Lin CY, Malatestinic WN, Goldblum OM, McLean RR, Crabtree MM, O'Brien J, Grace EL, Murage MJ. Shahriari M, et al. Among authors: malatestinic wn. J Dermatolog Treat. 2022 May;33(3):1538-1546. doi: 10.1080/09546634.2020.1853023. Epub 2020 Dec 2. J Dermatolog Treat. 2022. PMID: 33267635 Free article.
Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ, Princic N, Park J, Malatestinic WN, Zhu B, Atiya B, Kern SA, Stenger KB, Sprabery AT, Ogdie A. Murage MJ, et al. Among authors: malatestinic wn. J Manag Care Spec Pharm. 2022 Feb;28(2):206-217. doi: 10.18553/jmcp.2022.28.2.206. J Manag Care Spec Pharm. 2022. PMID: 35098751 Free PMC article.
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry.
Lebwohl M, Strober B, Schrader A, Li AH, Eckmann T, Zhu B, Malatestinic WN, Birt J, Feely M, Blauvelt A. Lebwohl M, et al. Among authors: malatestinic wn. Drugs Real World Outcomes. 2024 Sep;11(3):451-464. doi: 10.1007/s40801-024-00439-w. Epub 2024 Jun 24. Drugs Real World Outcomes. 2024. PMID: 38914857 Free PMC article.
48 results